Iovance Biotherapeutics (IOVA) Revenue (2023 - 2026)
Iovance Biotherapeutics (IOVA) posted quarterly Revenue of $71.4 million for Q1 2026, up 44.82% year-over-year from $49.3 million in Q1 2025, and down 17.68% quarter-over-quarter from $86.8 million in Q4 2025.
Iovance Biotherapeutics (IOVA) Revenue (2023 - 2026) Analysis & Trends
Iovance Biotherapeutics (IOVA) has reported Revenue for 4 consecutive years, with $71.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Revenue rose 44.82% year-over-year to $71.4 million; the TTM figure through Mar 2026 stood at $285.6 million (up 34.29% YoY), while the FY2025 annual figure was $263.5 million, up 60.6% from the prior year.
- Revenue declined to $71.4 million in Q1 2026 per IOVA's latest filing, from $86.8 million in the prior quarter.
- Across five years, Revenue topped out at $86.8 million in Q4 2025 and bottomed at $238000.0 in Q2 2023.
- Historically, Revenue has averaged $41.7 million across 4 years, with a median of $53.9 million in 2024.
- Annual changes were most pronounced in 2024 — Revenue jumped 15189.21% — and 2025, when it climbed 15.2%.
- Iovance Biotherapeutics' Revenue stood at $482000.0 in 2023, then surged by 15189.21% to $73.7 million in 2024, then grew by 17.74% to $86.8 million in 2025, then declined by 17.68% to $71.4 million in 2026.
- Business Quant data shows IOVA's Revenue at $71.4 million in Q1 2026, $86.8 million in Q4 2025, and $67.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.56 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.71 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3,001.92 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 674.14 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.29 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 425.49 Mn |
| 10 | Iovance Biotherapeutics | 3.16 Bn | 2.86 Bn | 55.72 Mn | 99.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 99.31 Mn |
| Mar 31, 2026 | 71.43 Mn |
| Dec 31, 2025 | 86.77 Mn |
| Sep 30, 2025 | 67.46 Mn |
| Jun 30, 2025 | 59.95 Mn |
| Mar 31, 2025 | 49.32 Mn |
| Dec 31, 2024 | 73.69 Mn |
| Sep 30, 2024 | 58.56 Mn |
| Jun 30, 2024 | 31.11 Mn |
| Mar 31, 2024 | 715,000.00 |
| Dec 31, 2023 | 482,000.00 |
| Sep 30, 2023 | 469,000.00 |
| Jun 30, 2023 | 238,000.00 |